Sonoma Pharmaceuticals (SNOA) Competitors $2.41 -0.47 (-16.32%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$2.54 +0.13 (+5.19%) As of 03/28/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNOA vs. NNVC, CVM, CGTX, LSTA, LPCN, ME, CLDI, EGRX, INAB, and MTEXShould you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include NanoViricides (NNVC), CEL-SCI (CVM), Cognition Therapeutics (CGTX), Lisata Therapeutics (LSTA), Lipocine (LPCN), 23andMe (ME), Calidi Biotherapeutics (CLDI), Eagle Pharmaceuticals (EGRX), IN8bio (INAB), and Mannatech (MTEX). These companies are all part of the "pharmaceutical products" industry. Sonoma Pharmaceuticals vs. NanoViricides CEL-SCI Cognition Therapeutics Lisata Therapeutics Lipocine 23andMe Calidi Biotherapeutics Eagle Pharmaceuticals IN8bio Mannatech Sonoma Pharmaceuticals (NASDAQ:SNOA) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, community ranking, analyst recommendations, dividends, earnings and institutional ownership. Do institutionals and insiders believe in SNOA or NNVC? 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 3.9% of Sonoma Pharmaceuticals shares are held by insiders. Comparatively, 4.6% of NanoViricides shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in SNOA or NNVC? Sonoma Pharmaceuticals received 216 more outperform votes than NanoViricides when rated by MarketBeat users. Likewise, 67.50% of users gave Sonoma Pharmaceuticals an outperform vote while only 0.00% of users gave NanoViricides an outperform vote. CompanyUnderperformOutperformSonoma PharmaceuticalsOutperform Votes21667.50% Underperform Votes10432.50% NanoViricidesOutperform VotesNo VotesUnderperform Votes57100.00% Which has higher valuation and earnings, SNOA or NNVC? Sonoma Pharmaceuticals has higher revenue and earnings than NanoViricides. NanoViricides is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSonoma Pharmaceuticals$13.97M0.28-$4.84M-$4.02-0.60NanoViricidesN/AN/A-$8.29M-$0.72-1.68 Is SNOA or NNVC more profitable? NanoViricides has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -26.82%. Sonoma Pharmaceuticals' return on equity of -68.98% beat NanoViricides' return on equity.Company Net Margins Return on Equity Return on Assets Sonoma Pharmaceuticals-26.82% -68.98% -26.39% NanoViricides N/A -87.90%-78.69% Does the media refer more to SNOA or NNVC? In the previous week, Sonoma Pharmaceuticals had 3 more articles in the media than NanoViricides. MarketBeat recorded 4 mentions for Sonoma Pharmaceuticals and 1 mentions for NanoViricides. NanoViricides' average media sentiment score of 1.00 beat Sonoma Pharmaceuticals' score of 0.79 indicating that NanoViricides is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sonoma Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NanoViricides 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, SNOA or NNVC? Sonoma Pharmaceuticals has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500. Comparatively, NanoViricides has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. SummarySonoma Pharmaceuticals beats NanoViricides on 9 of the 14 factors compared between the two stocks. Remove Ads Get Sonoma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNOA vs. The Competition Export to ExcelMetricSonoma PharmaceuticalsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.90M$4.35B$5.63B$7.84BDividend YieldN/A48.03%5.33%4.01%P/E Ratio-0.6028.4223.5518.73Price / Sales0.2849.26388.1990.75Price / CashN/A51.0838.1734.64Price / Book0.806.116.894.23Net Income-$4.84M$67.64M$3.20B$247.47M7 Day Performance-30.75%-5.25%-3.06%-2.29%1 Month Performance6.17%-4.12%1.51%-5.81%1 Year Performance1,349.19%10.65%9.35%-0.94% Sonoma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNOASonoma Pharmaceuticals0.3695 of 5 stars$2.41-16.3%N/A+1,349.2%$3.90M$13.97M-0.60180Short Interest ↑News CoverageGap UpNNVCNanoViricidesN/A$1.33+2.3%N/A+4.3%$20.80MN/A-1.8520News CoverageCVMCEL-SCIN/A$0.27+2.4%N/A-87.5%$20.56MN/A-0.5543Analyst ForecastHigh Trading VolumeCGTXCognition Therapeutics3.7383 of 5 stars$0.49+7.7%$7.50+1,431.2%-77.2%$20.35MN/A-0.5020Short Interest ↓Analyst RevisionGap UpLSTALisata Therapeutics3.0201 of 5 stars$2.33-2.1%$15.00+543.8%-24.7%$20.09M$1M-0.9330Short Interest ↓Gap DownLPCNLipocine2.075 of 5 stars$3.68+4.0%$10.00+171.7%-36.9%$19.69M$11.20M-4.8410ME23andMe1.2364 of 5 stars$0.73-59.2%$9.40+1,187.7%-94.3%$19.58M$208.78M-0.05770Options VolumeNews CoverageGap DownHigh Trading VolumeCLDICalidi Biotherapeutics2.204 of 5 stars$0.73-1.9%$15.00+1,966.4%N/A$19.21M$50,000.000.0038News CoverageGap DownEGRXEagle PharmaceuticalsN/A$1.45-2.7%N/A-83.2%$18.83M$257.55M0.00100Analyst ForecastNews CoverageGap UpINABIN8bio3.034 of 5 stars$0.23-2.1%$6.00+2,532.7%-83.4%$18.52MN/A-0.3020Short Interest ↑Gap UpMTEXMannatech0.6999 of 5 stars$9.62-0.8%N/A+7.4%$18.13M$121.55M-11.88250Earnings ReportAnalyst ForecastGap Up Remove Ads Related Companies and Tools Related Companies NanoViricides Competitors CEL-SCI Competitors Cognition Therapeutics Competitors Lisata Therapeutics Competitors Lipocine Competitors 23andMe Competitors Calidi Biotherapeutics Competitors Eagle Pharmaceuticals Competitors IN8bio Competitors Mannatech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNOA) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump to unlock 15-figure fortune for America (May 3rd) ?We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SNOA Stock Free SNOA Stock Alerts